LMP Capital and Income Fund Inc (SCD) Stock Price

15.01 ▲ +0.09 (+0.60%)
Open: 14.99 Vol: 40.6K Day's range: 14.95 - 15.06 Dec 05, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
SCD Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 15.00▲ 15.00▲ 14.97▲ 14.85▲ 14.63▲
MA10 14.90▲ 14.87▲ 14.85▲ 14.66▲ 14.90▲
MA20 14.81▲ 14.82▲ 14.79▲ 14.59▲ 15.14▼
MA50 14.72▲ 14.50▲ 14.48▲ 14.98▲ 15.69▼
MA100 14.44▲ 14.53▲ 14.57▲ 15.18▼ 15.70▼
MA200 14.54▲ 14.74▲ 14.90▲ 15.43▼ 14.25▲
  5 mins 30 mins Hourly Daily Weekly
MACD 0.025▲ 0.016▲ 0.019▲ 0.096▲ -0.032▼
RSI 71.628▲ 73.247▲ 72.796▲ 58.717▲ 47.054▼
STOCH 95.938▲ 95.216▲ 95.216▲ 89.914▲ 27.039    
WILL %R -7.500▲ -7.500▲ -7.500▲ -3.937▲ -43.256    
CCI 99.086     108.632▲ 133.168▲ 114.901▲ -38.179    
Latest Filters Detected On SCD
MA $SCD Price Crossed Above MA(50) Set Alert
▲ BREAK $SCD Price Breaks 20 Days High Set Alert
▲ BREAK $SCD Price Breaks 10 Days High Set Alert
CDL $SCD Doji Candlestick Pattern Detected Set Alert
LMP Capital and Income Fund Inc News
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American ...
Saturday, December 06, 2025 02:48 PM
Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 ...
Vertex presents new data on Casgevy at ASH
Saturday, December 06, 2025 07:00 AM
US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with ...
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease ...
Saturday, December 06, 2025 05:15 AM
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
SCD historical stock data
date open high low close volume
05/12/25 14.99 15.06 14.95 15.01 40,600
04/12/25 14.93 14.99 14.86 14.92 62,800
03/12/25 14.73 14.89 14.73 14.86 44,600
02/12/25 14.77 14.77 14.65 14.72 54,100
01/12/25 14.89 14.94 14.66 14.73 93,200
28/11/25 14.71 14.85 14.69 14.80 49,200
26/11/25 14.54 14.70 14.51 14.65 78,100
25/11/25 14.29 14.47 14.29 14.47 96,000
24/11/25 14.23 14.31 14.17 14.26 69,300
21/11/25 13.99 14.14 13.79 14.14 156,800
Quote Details
52wk Low:13.35
52wk High:17.86
Vol:40.6K
Avg Vol(3m):1.6M
1Y Chng:-10.17%
1M Chng:-0.07%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 248.40M